SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BFRI reported Q3 2026 results. The price and volatility reaction is pending.
BFRIearnings

Earnings reactions, page 2

Biofrontera Inc. (BFRI) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Net product revenue for the third quarter of 2026 was $9.1 million, an increase of 29.8% compared to $7.0 million in the prior-year period.
  • Gross margin was 74.4% for the third quarter of 2026, compared to 70.7% in the prior-year period.
  • Net loss for the third quarter of 2026 was $6.4 million, or $(0.42) per share, compared to a net loss of $6.6 million, or $(0.62) per share, in the prior-year period.
  • Non-GAAP Adjusted EBITDA for the third quarter of 2026 was $(5.5) million, compared to $(6.0) million in the prior-year period.
  • Cash and cash equivalents were $3.2 million as of September 30, 2026, compared to $6.4 million as of December 31, 2025.

Notes

Stock-based compensation for the nine months ended September 30, 2025 included in the non-GAAP Adjusted EBITDA reconciliation was revised from $0.4 million, as previously reported, to $0.7 million.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →